The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Background/aims: Accurate information on harms arising from medical interventions is essential for assessing benefit–risk ratios. Since 2004, there has been an extension of the Consolidated Standards of Reporting Trials statement for reporting harms data in publications on randomized clinical trials. The objective of our study was to assess the quality of this reporting from academic randomized clinical trials on drugs. Methods: We searched for articles on randomized clinical trials funded between 2004 and 2008 by the “Programme Hospitalier de Recherche Clinique.” We included all published randomized clinical trials that assessed drugs. Harm-related data were extracted and compared with the Consolidated Standards of Reporting Trials Harms extension, and the space in the articles devoted to harms data was measured. Results: In total, 37 randomized clinical trials met the inclusion criteria. The median harm score was 9/18. In 73.0% of the randomized clinical trials, the reporting of adverse events was selective. Less than 50% of articles provided information on reasons for drug discontinuation that were related to adverse events. The score and the space allocated to harms were higher in antineoplastic and immunomodulating drugs randomized clinical trials, while the median proportion of the space in the results section allocated to harms was 16.8%. In 67.6% of the articles, the space allocated to the authors’ list and affiliations was greater than the space in the results section allocated to descriptions of harms. No significant improvement in the score or the space allocation was observed during the study period. Conclusion: Reporting of harms in French academic drug randomized clinical trials is suboptimal; moreover, this shortcoming is a critical barrier to evaluating the benefit–risk ratio of drug randomized clinical trials. Thus, the authors should be encouraged to adhere to the Consolidated Standards of Reporting Trials Harms extension.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another important reason for data extraction errors might be the poor reporting of adverse events in randomised controlled trials, which have varying terminology, poorly defined categories, and diverse data sources. 30 31 32”
From Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study (2022) · cites this paper as [32]
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593 · cited 2×
“In particular, the recommendations included (1) mentioning harms in the title or abstract if safety is an objective, (2) clarifying how the information related to the AEs was collected, (3) describing discontinuations due to harms, (4) presenting frequencies per study arm and type of AE, and (5) including a balanced d…”
BackgroundLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaître, O., Cohen, P., Maurier, F., Decaux, O., Ninet, J., Gobert, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404231 · Cited by 1,090
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Laffay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8376 · Cited by 747
Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70560-0 · Cited by 744
Jabre, P., Combes, X., Lapostolle, F., Dhaouadi, M., Ricard-Hibon, A., Vivien, B., Bertrand, L., Beltramini, A., Gamand, P., Albizzati, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60949-1 · Cited by 562
Hopewell, S., Dutton, S., Yu, L.-M., Chan, A.-W., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c723 · Cited by 504 · cited 1×
“In the same manner, although the CONSORT statement had received widespread attention, adherence to it is still found to be incomplete, even though improvements concerning certain recommendations during successive years have been highlighted.(65,66) The assessment was performed by two independent persons using a standa…”
MethodBernard, L., Dinh, A., Ghout, I., Simo, D., Zeller, V., Issartel, B., Le Moing, V., Belmatoug, N., Lesprit, P., Bru, J.-P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61233-2 · Cited by 494
Treatment of Primary Sjögren Syndrome With Rituximab: A Randomized Trial
Devauchelle-Pensec, V., Mariette, X., Jousse-Joulin, S., Berthelot, J.-M., Perdriger, A., Puéchal, X., Le Guern, V., Sibilia, J., Gottenberg, J.-E., Chiche, L., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1085 · Cited by 429
Malka, D., Cervera, P., Foulon, S., Trarbach, T., de la Fouchardière, C., Boucher, E., Fartoux, L., Faivre, S., Blanc, J.-F., Viret, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70212-8 · Cited by 408
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 392
Baud, O., Maury, L., Lebail, F., Ramful, D., El Moussawi, F., Nicaise, C., Zupan-Simunek, V., Coursol, A., Beuchée, A., Bolot, P., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00202-6 · Cited by 364
Biondi, A., Schrappe, M., De Lorenzo, P., Castor, A., Lucchini, G., Gandemer, V., Pieters, R., Stary, J., Escherich, G., Campbell, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70377-7 · Cited by 330
High-dose tranexamic acid reduces blood loss in postpartum haemorrhage
Ducloy-Bouthors, A.-S., Jude, B., Duhamel, A., Broisin, F., Huissoud, C., Keita-Meyer, H., Mandelbrot, L., Tillouche, N., Fontaine, S., Le Goueff, F., et al. (2011) · Critical Care · doi:10.1186/cc10143 · Cited by 314
Gottenberg, J.-E., Ravaud, P., Puéchal, X., Le Guern, V., Sibilia, J., Goeb, V., Larroche, C., Dubost, J.-J., Rist, S., Saraux, A., et al. (2014) · JAMA · doi:10.1001/jama.2014.7682 · Cited by 311
Reporting of Safety Results in Published Reports of Randomized Controlled Trials
(2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.306 · Cited by 287
Kodjikian, L., Souied, E. H., Mimoun, G., Mauget-Faÿsse, M., Behar-Cohen, F., Decullier, E., Huot, L., & Aulagner, G. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.06.020 · Cited by 257
Adverse Events in Randomized Trials: Neglected, Restricted, Distorted, and Silenced
Ioannidis, J. P. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.313 · Cited by 243
Négrier, S., Gravis, G., Pérol, D., Chevreau, C., Delva, R., Bay, J.-O., Blanc, E., Ferlay, C., Geoffrois, L., Rolland, F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70124-3 · Cited by 239
Marfan Sartan: a randomized, double-blind, placebo-controlled trial
Milleron, O., Arnoult, F., Ropers, J., Aegerter, P., Detaint, D., Delorme, G., Attias, D., Tubach, F., Dupuis-Girod, S., Plauchu, H., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv151 · Cited by 217
Mathurin, P., Louvet, A., Duhamel, A., Nahon, P., Carbonell, N., Boursier, J., Anty, R., Diaz, E., Thabut, D., Moirand, R., et al. (2013) · JAMA · doi:10.1001/jama.2013.276300 · Cited by 210
Placebo-controlled trial of rituximab in IgM anti-myelin–associated glycoprotein neuropathy
Léger, J.-M., Viala, K., Nicolas, G., Créange, A., Vallat, J.-M., Pouget, J., Clavelou, P., Vial, C., Steck, A., Musset, L., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318296e92b · Cited by 208
Fizazi, K., Pagliaro, L., Laplanche, A., Fléchon, A., Mardiak, J., Geoffrois, L., Kerbrat, P., Chevreau, C., Delva, R., Rolland, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70490-5 · Cited by 207
Costedoat-Chalumeau, N., Galicier, L., Aumaître, O., Francès, C., Le Guern, V., Lioté, F., Smail, A., Limal, N., Perard, L., Desmurs-Clavel, H., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202322 · Cited by 205
Haïk, S., Marcon, G., Mallet, A., Tettamanti, M., Welaratne, A., Giaccone, G., Azimi, S., Pietrini, V., Fabreguettes, J.-R., Imperiale, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70307-7 · Cited by 203
Thévenot, T., Bureau, C., Oberti, F., Anty, R., Louvet, A., Plessier, A., Rudler, M., Heurgué-Berlot, A., Rosa, I., Talbodec, N., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.017 · Cited by 195
Moreau, C., Delval, A., Defebvre, L., Dujardin, K., Duhamel, A., Petyt, G., Vuillaume, I., Corvol, J.-C., Brefel-Courbon, C., Ory-Magne, F., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70106-0 · Cited by 192
Sautenet, B., Blancho, G., Büchler, M., Morelon, E., Toupance, O., Barrou, B., Ducloux, D., Chatelet, V., Moulin, B., Freguin, C., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000000958 · Cited by 187
Bent, S., Padula, A., & Avins, A. L. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-4-200602210-00007 · Cited by 177 · cited 1×
“The methods used to collect AEs information and the frequency of the collection have a direct impact on the number and scope of AEs reported.(1,2) To achieve meaningful comparisons between trials, knowledge of how AEs were assessed”
MethodPapazian, L. (2013) · JAMA · doi:10.1001/jama.2013.280031 · Cited by 176
Shamseer, L., Hopewell, S., Altman, D. G., Moher, D., & Schulz, K. F. (2016) · Trials · doi:10.1186/s13063-016-1408-z · Cited by 168 · cited 1×
“In the same manner, although the CONSORT statement had received widespread attention, adherence to it is still found to be incomplete, even though improvements concerning certain recommendations during successive years have been highlighted.(65,66) The assessment was performed by two independent persons using a standa…”
MethodAdverse Event Reporting in Cancer Clinical Trial Publications
Sivendran, S., Latif, A., McBride, R. B., Stensland, K. D., Wisnivesky, J. P., Haines, L., Oh, W. K., & Galsky, M. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.2219 · Cited by 167 · cited 3×
“In contrast, other studies found improvements in the global score, specific recommendations or space in results sections allocated during successive years or when comparing score before and after the publication of the CONSORT Harms extension in 2004.(13,16,56,59,62,63) Haidich et al.”
BackgroundResultWithdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
Ory‐Magne, F., Corvol, J., Azulay, J., Bonnet, A.-M., Brefel‐Courbon, C., Damier, P., Dellapina, E., Destée, A., Durif, F., Galitzky, M., et al. (2013) · Neurology · doi:10.1212/wnl.0000000000000050 · Cited by 162
Duval, X., van der Werf, S., Blanchon, T., Mosnier, A., Bouscambert‐Duchamp, M., Tibi, A., Enouf, V., Charlois-Ou, C., Vincent, C., Andréoletti, L., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000362 · Cited by 142
Pasquier, E., de Saint Martin, L., Bohec, C., Chauleur, C., Bretelle, F., Marhic, G., Le Gal, G., Debarge, V., Lecomte, F., Denoual-Ziad, C., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610857 · Cited by 125
Péron, J., Maillet, D., Gan, H. K., Chen, E. X., & You, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3981 · Cited by 125 · cited 3×
“In contrast, other studies found improvements in the global score, specific recommendations or space in results sections allocated during successive years or when comparing score before and after the publication of the CONSORT Harms extension in 2004.(13,16,56,59,62,63) Haidich et al.”
BackgroundResultPrey, S., Ezzedine, K., Doussau, A., Grandoulier, A.-S., Barcat, D., Chatelus, E., Diot, E., Durant, C., Hachulla, E., de Korwin-Krokowski, J.-D., et al. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11186.x · Cited by 105
Reporting of safety data from randomised trials
Ioannidis, J. P. A., & Contopoulos‐Ioannidis, D. G. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79825-1 · Cited by 97
Haidich, A., Birtsou, C., Dardavessis, T., Tirodimos, I., & Arvanitidou, M. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.005 · Cited by 95 · cited 6×
“This proportion was less impressive in other studies (36.5% for Haidich et al.,13 47.9% for Ioannidis and Lau9) or similar for Turner et al.,11 who reported that less than 30% of trials devoted an equal or greater percentage of words to the reporting of safety than to authors’ affiliations.”
BackgroundResultInfluentialBenamouzig, R., Uzzan, B., Deyra, J., Martin, A., Girard, B., Little, J., & Chaussade, S. (2011) · Gut · doi:10.1136/gutjnl-2011-300113 · Cited by 91
Randomized Trial of Oral Versus Sequential IV/Oral Antibiotic for Acute Pyelonephritis in Children
Bocquet, N., Sergent-Alaoui, A., Jais, J.-P., Gajdos, V., Guigonis, V., Lacour, B., & Chéron, G. (2012) · PEDIATRICS · doi:10.1542/peds.2011-0814 · Cited by 90
Dechartres, A., Charles, P., Hopewell, S., Ravaud, P., & Altman, D. G. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.015 · Cited by 87 · cited 1×
“These criteria are open to individual interpretation and can explain the variety of items used in the studies performed on the subject.(67) Using a score in which each item was of equal importance, as implemented in other studies, may be subject to debate.”
MethodOutpatient Cervical Ripening by Nitric Oxide Donors for Prolonged Pregnancy
Schmitz, T., Fuchs, F., Closset, E., Rozenberg, P., Winer, N., Perrotin, F., Verspyck, É., Azria, É., Carbonne, B., Lepercq, J. A., et al. (2014) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000000544 · Cited by 82
Pateron, D., Vicaut, É., Debuc, E., Sahraoui, K., Carbonell, N., Bobbia, X., Thabut, D., Adnet, F., Nahon, P., Amathieu, R., et al. (2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.01.001 · Cited by 80
Smith, S. M., Chang, D. R., Pereira, A. C., Shah, N., Gilron, I., Katz, N. P., Lin, A. H., McDermott, M., Rappaport, B. A., Rowbotham, M. C., et al. (2012) · Pain · doi:10.1016/j.pain.2012.08.009 · Cited by 70 · cited 2×
“In contrast, other studies found improvements in the global score, specific recommendations or space in results sections allocated during successive years or when comparing score before and after the publication of the CONSORT Harms extension in 2004.(13,16,56,59,62,63) Haidich et al.”
BackgroundResultAdverse events: the more you search, the more you find
Ioannidis, J. P. A., Mulrow, C. D., & Goodman, S. N. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-4-200602210-00013 · Cited by 69 · cited 1×
“The methods used to collect AEs information and the frequency of the collection have a direct impact on the number and scope of AEs reported.(1,2) To achieve meaningful comparisons between trials, knowledge of how AEs were assessed”
MethodReporting of Harm in Randomized Controlled Trials Published in the Urological Literature
Breau, R. H., Gaboury, I., Scales, C. D., Fesperman, S. F., Watterson, J. D., & Dahm, P. (2010) · Journal of Urology · doi:10.1016/j.juro.2010.01.030 · Cited by 58 · cited 1×
“Other studies found that some characteristics from trials or articles were associated with higher quality harms reporting, such as the origin of funding or impact factor.(7,13,15,16,58,59,61,62) We expected an increase of scores over years.”
BackgroundLow quality of reporting adverse drug reactions in paediatric randomised controlled trials
de Vries, T. W., & van Roon, E. N. (2010) · Archives of Disease in Childhood · doi:10.1136/adc.2009.175562 · Cited by 57 · cited 3×
“Other studies found that some characteristics from trials or articles were associated with higher quality harms reporting, such as the origin of funding or impact factor.(7,13,15,16,58,59,61,62) We expected an increase of scores over years.”
BackgroundMethodPrunier, F., Bière, L., Gilard, M., Boschat, J., Mouquet, F., Bauchart, J.-J., Charbonnier, B., Genée, O., Guérin, P., Warin‐Fresse, K., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.11.005 · Cited by 55
Chowers, M. Y., Gottesman, B. S., Leibovici, L., Pielmeier, U., Andreassen, S., & Paul, M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp191 · Cited by 53 · cited 1×
“In contrast, other studies found improvements in the global score, specific recommendations or space in results sections allocated during successive years or when comparing score before and after the publication of the CONSORT Harms extension in 2004.(13,16,56,59,62,63) Haidich et al.”
ResultTurner, L.-A., Singh, K., Garritty, C., Tsertsvadze, A., Manheimer, E., Wieland, L. S., Galipeau, J., & Moher, D. (2011) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-11-67 · Cited by 50 · cited 5×
“This proportion was less impressive in other studies (36.5% for Haidich et al.,13 47.9% for Ioannidis and Lau9) or similar for Turner et al.,11 who reported that less than 30% of trials devoted an equal or greater percentage of words to the reporting of safety than to authors’ affiliations.”
BackgroundResultInfluentialCornelius, V. R., Sauzet, O., Williams, J. E., Ayis, S., Farquhar-Smith, P., Ross, J. R., Branford, R. A., & Peacock, J. L. (2013) · Pain · doi:10.1016/j.pain.2012.08.012 · Cited by 49
Ethgen, M., Boutron, I., Baron, G., Giraudeau, B., Sibilia, J., & Ravaud, P. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-1-200507050-00006 · Cited by 49 · cited 1×
“In the same way, harms data were more often described in pharmacologic treatment reports than in nonpharmacological treatment reports.(60) Other studies found that some characteristics from trials or articles were associated with higher quality harms reporting, such as the origin of funding or impact factor.”
ResultShukralla, A. A., Smith, C. T., Powell, G. A., Williamson, P. R., & Marson, A. G. (2011) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.06.015 · Cited by 45 · cited 1×
“Other studies found that some characteristics from trials or articles were associated with higher quality harms reporting, such as the origin of funding or impact factor.(7,13,15,16,58,59,61,62) We expected an increase of scores over years.”
BackgroundAdverse Event Reporting in Acupuncture Clinical Trials Focusing on Pain
Capili, B., Anastasi, J. K., & Geiger, J. N. (2010) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e3181b2c985 · Cited by 41 · cited 1×
“’’ This situation concerns not only pharmacologic treatments but also nonpharmacologic treatments.(8,10,11) The objective of our study was to assess the quality of reporting of harm-related data from drug RCTs funded by the ‘‘Programme Hospitalier de Recherche Clinique’’ (PHRC).”
BackgroundThe effect of a single dose of oral ivermectin on pruritus in the homeless
Badiaga, S., Foucault, C., Rogier, C., Doudier, B., Rovery, C., Tissot‐Dupont, H., Castro, P., Raoult, D., & Brouqui, P. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn161 · Cited by 39
Bagul, N. B., & Kirkham, J. J. (2012) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2012.681724 · Cited by 34 · cited 1×
“Similar to other studies, we chose not to include recommendation 9 in our extraction form, as subgroup analyses were not performed in any of the selected articles.(6,7,14,15,59) Therefore, the scores were not penalized by one point.”
Maggi, C. B., Griebeler, I. H., & Pizzol, T. D. S. D. (2014) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-140609 · Cited by 19
Carmichael, K., Nevitt, S. J., Weston, J., Smith, C. T., & Marson, A. G. (2015) · Epilepsy Research · doi:10.1016/j.eplepsyres.2015.04.019 · Cited by 18 · cited 2×
“In contrast, other studies found improvements in the global score, specific recommendations or space in results sections allocated during successive years or when comparing score before and after the publication of the CONSORT Harms extension in 2004.(13,16,56,59,62,63) Haidich et al.”
BackgroundResultChen, B., Jian, L., Zhang, C., & Li, M. (2014) · Trials · doi:10.1186/1745-6215-15-128 · Cited by 15 · cited 2×
“Chen et al.(64) found that the correlation between the score of overall reporting quality and year of publications explained significantly 35% of the variance of the score.”
BackgroundEthgen, M., Boutron, I., Steg, P. G., Roy, C., & Ravaud, P. (2009) · Trials · doi:10.1186/1745-6215-10-29 · Cited by 13 · cited 2×
“’’ This situation concerns not only pharmacologic treatments but also nonpharmacologic treatments.(8,10,11) The objective of our study was to assess the quality of reporting of harm-related data from drug RCTs funded by the ‘‘Programme Hospitalier de Recherche Clinique’’ (PHRC).”
BackgroundReporting of harms by randomised controlled trials in ophthalmology
O’Day, R., Walton, R., Blennerhassett, R. C., Gillies, M. C., & Barthelmes, D. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304687 · Cited by 6
Completeness of Safety Reporting in Randomized Trials: An Evaluation of 7 Medical Areas
Ioannidis, J. P. A., & Lau, J. (2001) · JAMA · doi:10.1001/jama.285.4.437 · Cited by 3 · cited 1×
“8% of the results section space).(8,9,11,13,15) This potential bias in reporting favorable efficacy outcomes may be related to the assumption that toxicity outcomes are less important to readers than efficacy results or to space limitations imposed by journals.”
BackgroundMaggi, C. B., Griebeler, I. H., & Pizzol, T. D. S. D. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.12.006 · Cited by 2
Research works printed but not linked: 1
- Rozenberg P, 2012, Am J Obstet Gynecol, 206, 206
Cited by
Junqueira, D. R., Zorzela, L., Golder, S., Loke, Y., Gagnier, J. J., Julious, S. A., Li, T., Mayo-Wilson, E., Pham, B., Phillips, R., et al. (2023) · BMJ · doi:10.1136/bmj-2022-073725 · Cited by 281
Analysis and reporting of adverse events in randomised controlled trials: a review
Phillips, R., Hazell, L., Sauzet, O., & Cornelius, V. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024537 · Cited by 228
Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study
Xu, C., Yu, T., Furuya-Kanamori, L., Lin, L., Zorzela, L., Zhou, X., Dai, H., Loke, Y., & Vohra, S. (2022) · BMJ · doi:10.1136/bmj-2021-069155 · Cited by 82
Junqueira, D. R., Zorzela, L., Golder, S., Loke, Y., Gagnier, J. J., Julious, S. A., Li, T., Mayo-Wilson, E., Pham, B., Phillips, R., et al. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.04.005 · Cited by 67
Phillips, R., Sauzet, O., & Cornelius, V. R. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-01167-9 · Cited by 39
“Methods that propose graphical approaches to view single or multiple AEs as the principal analysis method.”
BackgroundInfluential
Metadata
- Authors
- Favier, R., & Crépin, S.
- Affiliations
- Centre Hospitalier Universitaire de Limoges (FR)
- Corresponding author
- Crépin, Sabrina
- ORCID
- Crépin, Sabrina
- Venue
- Clinical Trials
- Publisher
- SAGE Publications
- Published
- 2018-03-02
- Volume
- 15
- Issue
- 3
- Pages
- 257-267
- ISSN
- 1740-7745 (ISSN-L)
- 1740-7753
- OpenAlex
- W2790844534
- Cited by
- 19
- References
- 66
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 3
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Clinical Trials (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- harms reporting, adverse events, risk-benefit assessment, clinical drug trials, reporting quality, anticancer agents, immunomodulators
- MeSH terms
- Data Accuracy, Adult, Child, Preschool, France, Humans, Periodicals as Topic, Publishing, Research Design, Randomized Controlled Trials as Topic, Adverse Drug Reaction Reporting Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.